Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00143273
Status:
COMPLETED
Last Update Posted:
2011-08-10
First Post:
2005-08-31
Brief Title:
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
Sponsor:
Ligand Pharmaceuticals
Organization:
Ligand Pharmaceuticals
Study Overview
Official Title:
Dose Response Study Of Lasofoxifene In Postmenopausal Women With Osteoporosis Placebo-Controlled Multicenter Double-Blind Comparative Study - Japanese Asian Dose Evaluation JADE
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
JADE
Brief Summary:
To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None